Estrogen-based hormone therapy in women with primary ovarian insufficiency

a systematic review

Nydia Burgos, Dahima Cintron, Paula Latortue-Albino, Valentina Serrano, Rene Rodriguez Gutierrez, Stephanie Faubion, Gabriela Spencer-Bonilla, Patricia J. Erwin, Mohammad H Murad

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods: A comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results: The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions: Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalEndocrine
DOIs
StateAccepted/In press - Oct 16 2017

Fingerprint

Primary Ovarian Insufficiency
Estrogens
Hormones
Therapeutics
Bone Density
Cohort Studies
Databases
Librarians
Conjugated (USP) Estrogens
Bone and Bones
Medroxyprogesterone Acetate
Mortality
Health
Gonadal Steroid Hormones
Women's Health
MEDLINE
Observational Studies
Estradiol
Randomized Controlled Trials
Myocardial Infarction

Keywords

  • Cardiovascular
  • Estrogen
  • Fracture
  • Lipids
  • Ovarian insufficiency
  • Quality of life

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Burgos, N., Cintron, D., Latortue-Albino, P., Serrano, V., Rodriguez Gutierrez, R., Faubion, S., ... Murad, M. H. (Accepted/In press). Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine, 1-13. https://doi.org/10.1007/s12020-017-1435-x

Estrogen-based hormone therapy in women with primary ovarian insufficiency : a systematic review. / Burgos, Nydia; Cintron, Dahima; Latortue-Albino, Paula; Serrano, Valentina; Rodriguez Gutierrez, Rene; Faubion, Stephanie; Spencer-Bonilla, Gabriela; Erwin, Patricia J.; Murad, Mohammad H.

In: Endocrine, 16.10.2017, p. 1-13.

Research output: Contribution to journalArticle

Burgos, N, Cintron, D, Latortue-Albino, P, Serrano, V, Rodriguez Gutierrez, R, Faubion, S, Spencer-Bonilla, G, Erwin, PJ & Murad, MH 2017, 'Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review', Endocrine, pp. 1-13. https://doi.org/10.1007/s12020-017-1435-x
Burgos N, Cintron D, Latortue-Albino P, Serrano V, Rodriguez Gutierrez R, Faubion S et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine. 2017 Oct 16;1-13. https://doi.org/10.1007/s12020-017-1435-x
Burgos, Nydia ; Cintron, Dahima ; Latortue-Albino, Paula ; Serrano, Valentina ; Rodriguez Gutierrez, Rene ; Faubion, Stephanie ; Spencer-Bonilla, Gabriela ; Erwin, Patricia J. ; Murad, Mohammad H. / Estrogen-based hormone therapy in women with primary ovarian insufficiency : a systematic review. In: Endocrine. 2017 ; pp. 1-13.
@article{e5f1c0ee2c954df6a05f61ecf3dae7e5,
title = "Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review",
abstract = "Purpose: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods: A comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results: The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions: Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.",
keywords = "Cardiovascular, Estrogen, Fracture, Lipids, Ovarian insufficiency, Quality of life",
author = "Nydia Burgos and Dahima Cintron and Paula Latortue-Albino and Valentina Serrano and {Rodriguez Gutierrez}, Rene and Stephanie Faubion and Gabriela Spencer-Bonilla and Erwin, {Patricia J.} and Murad, {Mohammad H}",
year = "2017",
month = "10",
day = "16",
doi = "10.1007/s12020-017-1435-x",
language = "English (US)",
pages = "1--13",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",

}

TY - JOUR

T1 - Estrogen-based hormone therapy in women with primary ovarian insufficiency

T2 - a systematic review

AU - Burgos, Nydia

AU - Cintron, Dahima

AU - Latortue-Albino, Paula

AU - Serrano, Valentina

AU - Rodriguez Gutierrez, Rene

AU - Faubion, Stephanie

AU - Spencer-Bonilla, Gabriela

AU - Erwin, Patricia J.

AU - Murad, Mohammad H

PY - 2017/10/16

Y1 - 2017/10/16

N2 - Purpose: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods: A comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results: The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions: Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.

AB - Purpose: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI. Methods: A comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study. Results: The search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent. Conclusions: Evidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.

KW - Cardiovascular

KW - Estrogen

KW - Fracture

KW - Lipids

KW - Ovarian insufficiency

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85031904796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031904796&partnerID=8YFLogxK

U2 - 10.1007/s12020-017-1435-x

DO - 10.1007/s12020-017-1435-x

M3 - Article

SP - 1

EP - 13

JO - Endocrine

JF - Endocrine

SN - 1355-008X

ER -